We sought to determine if the solvent in the formulation of etomidate is responsible for haemolysis in patients. In a randomized, prospective, double-blind study of 49 patients undergoing otolaryngological surgery, patients received etomidate dissolved in propylene glycol or in lipid emulsion. We first suspected that etomidate formulated in propylene glycol causes haemolysis after observing a reddish discolouration of the sera of volunteers treated with etomidate dissolved in propylene glycol. 1 We suspected that this reflected intravascular haemolysis caused by the high osmolality of etomidate (4965 mosmol litre
Summary
We sought to determine if the solvent in the formulation of etomidate is responsible for haemolysis in patients. In a randomized, prospective, double-blind study of 49 patients undergoing otolaryngological surgery, patients received etomidate dissolved in propylene glycol or in lipid emulsion. Concentrations of free haemoglobin and haptoglobin were measured before and for up to 360 min after injection of etomidate. We first suspected that etomidate formulated in propylene glycol causes haemolysis after observing a reddish discolouration of the sera of volunteers treated with etomidate dissolved in propylene glycol. 1 We suspected that this reflected intravascular haemolysis caused by the high osmolality of etomidate (4965 mosmol litre 91 ) dissolved in propylene glycol. 2 In this study we attempted to confirm the hypothesis that etomidate dissolved in propylene glycol causes haemolysis and that this is not associated with a more physiological solvent (lipid emulsion). In lipid emulsion, etomidate has a near physiological osmolality of 400 mosmol litre 91 .
Methods and results
After obtaining Institutional Review Board approval and informed consent, we studied 49 patients undergoing otolaryngological surgery, randomly allocated to receive etomidate in propylene glycol or in a lipid emulsion preparation for induction of anaesthesia. On the evening before and 1 h before operation, each patient was premedicated with lormetazepam 2 mg orally. Patients were given fentanyl 2 g kg 91 i.v. and atracurium 0.07 mg kg 91 i.v. for induction for anaesthesia, followed 3 min later by etomidate 0.3 mg kg 91 i.v. Patients in the propylene glycol group received Hypnomidate (Janssen, Neuss, Germany), etomidate 2 mg ml 91 of an aqueous solution of 35 vol% propylene glycol. Patients in the lipid emulsion group received EtomidateLipuro (B. Braun, Melsungen, Germany), etomidate 2 mg ml 91 of fat emulsion consisting of soy bean oil, medium-chain triglycerides, egg lecithin and glycerol. Neuromuscular block was produced with atracurium 0.5 mg kg 91 i.v. before tracheal intubation. During induction with etomidate, patients' lungs were ventilated with oxygen; subsequently, they were ventilated using a mask and 1-1.5% isoflurane in oxygen without nitrous oxide. After tracheal intubation, anaesthesia was maintained with 0.5-1.2% isoflurane and 65% nitrous oxide in oxygen. During operation, fentanyl i.v. was administered as needed. At the end of surgery, all patients were given droperidol 1.25-2.5 mg i.v. A second dose of etomidate was not given during anaesthesia. Patients also received an infusion of 1500 ml of a balanced electrolyte solution to reduce the dilution effect of blood sampling.
To record and quantify haemolysis, free haemoglobin concentrations in plasma before and 5 min after administration of etomidate were measured by an antigen-antibody nephelometer test. As an additional measure of haemolysis, haptoglobin concentrations in serum were measured by enzyme immunoassay before and 120, 240 and 360 min after administration of etomidate. At each measurement time, packed cell volume (PCV) was also measured, and correction in haptoglobin concentrations was made for the dilution effect. 
Comment
Several adverse effects caused by propylene glycol have been described: hypotension, pain on injection, lactic acidosis and pulmonary hypertension. 1 3-5 In our study, a single injection of etomidate 0.3 mg kg 91 dissolved in propylene glycol increased free haemoglobin (514%) and decreased serum haptoglobin (52.8%) concentrations significantly, indicating intravascular haemolysis. Free haemoglobin is bound within a few minutes by haptoglobin, forming a haptoglobinhaemoglobin complex. The half-life of haptoglobin is 3-4 days compared with that of the haptoglobinhaemoglobin complex of only 8 min. If intravascular free haemoglobin increases, haptoglobin concentration decreases, which is a measurable sign of haemolysis.
Haemolysis and cell lysis associated with an induction dose of etomidate dissolved in propylene glycol may not cause detectable renal injury in healthy individuals. However, several other drugs are also dissolved in propylene glycol such as lorazepam (osmolality 12800 mosmol litre
91
) and nitroglycerin (osmolality 4550 mosmol litre
). 2 Combined use of drugs dissolved in propylene glycol may increase the likelihood and severity of haemolysis. If etomidate dissolved in propylene glycol or other drugs with similar formulations are injected repeatedly after short intervals, or if they are used in combination, circulating haptoglobin may be depleted completely. Under such circumstances free haemoglobin from haemolysis may exceed binding capacity and exert toxic effects. 6 Intraoperative autotransfusion in patients who have received etomidate dissolved in propylene glycol also makes haemolysis problematic. It has been shown that infusion of packed red cells, especially from autotransfusion, decreases haptoglobin concentrations. 7 In fact, haptoglobin was undetectable in seven of 47 patients after autotransfusion. Etomidate is a desirable induction agent for older, less healthy patients because it does not effect cardiovascular stability. These patients often undergo procedures (total hip replacement or vascular surgery) that use autotransfusion. In such patients, the combined effects of etomidate in propylene glycol and autotransfusion may decrease haptoglobin concentrations. We speculate that those likely to be affected include patients with other risk factors, such as impaired renal function or patients in shock who need high re-transfusion volumes.
Our results are consistent with the hypothesis that propylene glycol is a less safe vehicle than lipid emulsion for etomidate. Side effects associated with propylene glycol may be toxic for some patients. 
